AI-Powered Biochip Detects Genetic Markers in 20 Minutes
Scientists at Nanyang Technological University have unveiled an AI‑powered nanophotonic biochip that detects multiple microRNA biomarkers in about 20 minutes, eliminating the need for PCR amplification. The platform uses a light‑trapping nanocavity to boost fluorescent signals and a Mask R‑CNN model to analyse thousands of signals in a single snapshot. Tests on lung‑cancer cell extracts demonstrated detection of three cancer‑related microRNAs with over 99% accuracy. The compact prototype pairs a colour camera with a mobile‑app, positioning the technology for point‑of‑care and large‑scale screening applications.
Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program
Johnson & Johnson’s hematology division secured FDA approval for a new multiple myeloma regimen—Tecvayli plus Darzalex Faspro—through the FDA Commissioner’s National Priority Voucher pilot. The approval came just 55 days after filing, marking the first blood‑cancer therapy to use the voucher...
FDA Looks East—Here’s What Industry Needs to Know
The FDA’s FY2027 budget proposes $2.5 million and five new full‑time staff to open foreign offices in Hanoi, Vietnam, and Tokyo, Japan, expanding its inspection footprint in East Asia. The request follows FY2026 congressional language urging permanent presence for unannounced inspections...
Organon’s VTAMA® (Tapinarof) Cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon announced that its steroid‑free VTAMA® (tapinarof) 1% cream received a strong, evidence‑based recommendation in the American Academy of Dermatology’s 2026 pediatric atopic dermatitis (AD) guidelines. The AAD highlighted VTAMA as the only topical treatment with high‑certainty evidence that is...
Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology
This week’s biotech financing spotlighted platform‑driven innovation in oncology and immunology. Adcendo closed a $75 million Series C to expand its ADC pipeline, while Beeline Medicines launched with $300 million Series A to develop precision autoimmune therapies. Harbinger Health secured $100 million for its multi‑cancer...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
Precision BioSciences received Clinical Trial Application approval to add sites in France and Romania to its global ELIMINATE‑B study of PBGENE‑HBV, an in‑vivo gene‑editing therapy for chronic hepatitis B. The expansion joins existing locations in the United Kingdom, Moldova, New Zealand, Hong Kong...
Homoharringtonine as a Senotherapeutic Drug
Researchers used a large‑scale drug‑repositioning screen to identify homoharringtonine (HHT), an FDA‑approved anti‑leukemic agent, as a potent senotherapeutic. In vitro, HHT selectively eliminated senescent pre‑adipocytes while sparing healthy cells. In male mice, HHT cleared senescent adipocytes, restored white‑adipose tissue function,...
A New Standard for Copay Excellence: Q&A with Brian Laird
Pharmaceutical manufacturers are confronting escalating out‑of‑pocket costs, high‑deductible plans and fragmented payer rules, prompting a shift from static copay reimbursements to strategic, data‑driven solutions. EVERSANA, which already processes over 12 million claims for 1.5 million patients, launched its Intelligent Copay Solution to...
How Are Regulatory Factors Impacting Biosimilars
The FDA issued draft guidance in March that would drop certain pharmacokinetic (PK) studies for biosimilars, aiming to lower development costs. At the same time, the Inflation Reduction Act (IRA) and most‑favored‑nation (MFN) pricing provisions are reshaping how manufacturers price...
Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell — Episode 251
In episode 251 of the Xtalks Life Science Podcast, Kevin Caldwell, CEO and co‑founder of Ossium Health, discusses the company’s pioneering off‑the‑shelf bone‑marrow therapy derived from deceased organ donors. The treatment aims to solve long‑standing clinical and logistical hurdles in...
Viewpoint: CRISPR and mRNA — Under Attack by Technology Skeptics — Poised to Save Millions of Children with Rare Diseases
Rare genetic diseases affect roughly 25 million Americans and generate about $400 billion in annual medical costs, yet fewer than five percent have FDA‑approved therapies. The scarcity of treatments stems from the economics of drug development for tiny patient pools. Recent breakthroughs...
Major Organoids Companies Plus Latest TechBio News
The latest TechBio briefing spotlights the fastest‑growing private organoid firms, highlighting recent Series A‑C rounds that collectively raised over $500 million. Leaders such as OrganoTech, CellSphere, and BioMimic are scaling production pipelines to meet demand from pharma, diagnostics, and personalized‑medicine partners. The...
Sonodynamic Therapy with Ferrocene-Modified Frameworks Targets Breast Cancer Metastasis
Researchers at Beijing Institute of Technology have engineered ferrocene‑modified covalent organic frameworks (mCOFs) that act as ultrasound‑activated sonosensitizers. When combined with sonodynamic therapy, the nanoplatform reduces breast cancer cell viability to 24.3% and drives apoptosis above 84%, while simultaneously generating...
Top 20 Most Innovative Healthcare Companies in 2026, Per Fast Company
Fast Company’s 2026 list spotlights the 20 most innovative healthcare firms, ranging from biotech pioneers like Children’s Hospital of Philadelphia’s CRISPR therapy to digital‑health platforms such as Lantern and Maven Clinic. The rankings arrive amid a surge in drug approvals—46...
Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
AbbVie signed an exclusive licensing deal with China’s Haisco Pharmaceutical to develop, manufacture and sell a suite of novel pain compounds outside mainland China, Hong Kong and Macau. The agreement provides Haisco $30 million upfront and up to $715 million in milestone payments,...
